Your heart is racing. Not in the way it does when you are frightened or in love — in the way it does when you have simply stood up from a chair. Within seconds of becoming upright, your pulse climbs thirty, forty, fifty beats per minute above baseline. Your vision dims at the edges. Your head fills with a pressure that is not quite pain and not quite dizziness but something in between, a bodily wrongness that most people who have never experienced it will struggle to name. Your hands are pale. Your legs are mottled. You are not anxious. You are not deconditioned. You are not making it up. Your autonomic nervous system — the part of your nervous system that is supposed to manage all of this automatically — is not doing its job. And in most healthcare encounters, this will be the beginning of a very long conversation in which someone tries very hard to convince you that it is.

Dysautonomia is not a single condition. It is a category — an umbrella term covering any disorder that impairs the function of the autonomic nervous system (ANS), the vast, largely invisible regulatory network that controls the body's involuntary functions. Heart rate, blood pressure, digestion, respiratory rate, pupil dilation, sweating, bladder function, sexual response, body temperature: all of these are governed by the autonomic nervous system without conscious input. When this system malfunctions, the consequences are as diverse and multi-systemic as its functions — which is, in part, why dysautonomia is so frequently missed, misattributed, and dismissed.

The most common and most studied form of dysautonomia is Postural Orthostatic Tachycardia Syndrome — POTS. It is, in the strict sense, neither rare nor esoteric. Estimates suggest it affects between one and three million people in the United States alone, with global numbers that dwarf that figure. And yet the average time from symptom onset to correct diagnosis in POTS has, until very recently, been measured in years — often four to six, sometimes more than a decade. The reason is not that the condition is obscure. It is that the medical system has been structurally unsuited to finding it — and that the people who have it have, with numbing consistency, been redirected toward explanations that serve the system's limitations rather than their actual pathology.

The Physiology

What the Autonomic Nervous System Does — and What Happens When It Doesn't

To understand dysautonomia, it helps to understand what the autonomic nervous system is designed to do — because its scope is staggering. The ANS operates in two primary branches: the sympathetic nervous system, which prepares the body for action (accelerating heart rate, elevating blood pressure, diverting blood to muscles, dilating pupils), and the parasympathetic nervous system, which promotes rest, recovery, and digestion. In health, these two branches operate in continuous, dynamic balance — adjusting and counter-adjusting in response to posture, activity, emotional state, environmental temperature, and the demands of every organ system simultaneously.

One of the most physiologically demanding tasks the ANS performs is the regulation of cardiovascular function in response to changes in posture. When a healthy person stands up from a lying or seated position, approximately 500 to 700 millilitres of blood pools in the lower extremities and abdominal vessels under the force of gravity. The ANS detects this shift via baroreceptors — pressure sensors located primarily in the aorta and carotid arteries — and responds within seconds: increased heart rate, increased cardiac output, peripheral vasoconstriction, activation of the renin-angiotensin-aldosterone axis to retain fluid. The net result is that blood pressure and cerebral perfusion are maintained, and the person stands up, stabilises, and continues with their life.

In POTS, this compensation fails. The exact mechanism varies across subtypes — and the diversity of subtypes is itself a major reason why the condition is so poorly understood — but the common result is that standing produces an excessive and sustained increase in heart rate without a corresponding fall in blood pressure. By consensus definition, POTS is diagnosed when there is a sustained heart rate increase of 30 beats per minute or more (or to above 120 bpm) within ten minutes of moving from a supine to a standing position, in the absence of orthostatic hypotension (a fall in blood pressure), in association with symptoms of orthostatic intolerance.

The heart rate number is, in a clinical sense, the least important part of that definition. It is a measurement that captures one consequence of a much larger regulatory failure. The patient's lived experience is not a number on a monitor. It is the inability to stand at a kitchen counter for the time it takes to make a cup of tea. It is sitting on the floor of the supermarket because reaching the checkout involved more vertical time than the body would permit. It is the daily arithmetic of upright minutes — how many do I have today, and what do I spend them on — that becomes the invisible calculus around which an entire life is reorganised.

"My cardiologist told me my heart was fine. My heart rate was 140 when I was standing in his office while he said this. He said it was anxiety. I had been told it was anxiety for four years. Nobody had ever simply counted my pulse while I was standing up and compared it to my pulse lying down. That was all it took. That and someone who thought to look."

The Subtypes

POTS Is Not One Thing — The Distinct Physiological Subtypes

One of the most consequential mistakes in the clinical management of POTS is treating it as a single, uniform condition. It is not. POTS is a syndrome — a collection of signs and symptoms that can arise from several distinct underlying mechanisms. The subtypes have different pathophysiology, different optimal treatments, and sometimes directly contraindicated treatments, meaning that a management strategy appropriate for one subtype may be actively harmful in another. This is not a theoretical concern. It is a practical one that affects patient outcomes every day in clinics that have not been adequately trained in the distinction.

Neuropathic POTS

The most common subtype. Caused by partial autonomic neuropathy, particularly affecting the small-fibre sympathetic nerves that innervate the blood vessels of the lower limbs and splanchnic circulation. Without appropriate peripheral vasoconstriction, blood pools in the lower body on standing, triggering reflex tachycardia. Skin biopsy for small-fibre nerve density and sweat testing (QSART) can support diagnosis.

Hyperadrenergic POTS

Characterised by an exaggerated sympathetic response to standing, with elevated norepinephrine levels (above 600 pg/mL) in the upright position. These patients often experience a rise in blood pressure as well as heart rate on standing, and may report hypertensive episodes, palpitations, and a paradoxical worsening with increased salt and fluid intake — the opposite of what other subtypes need. Clonidine or beta-blockade in low doses may be more appropriate than volume loading.

Hypovolemic POTS

Driven by reduced circulating blood volume — patients with this subtype have measurably low plasma volume, which is compounded by impaired aldosterone response and reduced renin-angiotensin-aldosterone axis activity. Aggressive fluid and salt repletion is the cornerstone of management. Frequently overlaps with neuropathic POTS. Common in those with connective tissue disorders (hEDS), where vessel wall laxity contributes to pathological venous pooling.

Post-Infectious / Secondary POTS

POTS that develops following a viral or bacterial infection, most prominently following COVID-19 (Long COVID-associated POTS is now one of the most commonly described post-infectious autonomic syndromes in medical literature). May involve autoimmune mechanisms including autoantibodies directed against adrenergic and muscarinic receptors. Mast cell activation is frequently a co-trigger. Onset is typically acute, with symptoms beginning days to weeks after infection.

These subtypes frequently overlap — a patient may have elements of neuropathic and hypovolemic POTS simultaneously, with a post-infectious trigger superimposed on an underlying connective tissue disorder. This overlap makes definitive subtyping difficult and requires specialist evaluation including autonomic function testing, plasma catecholamine levels in orthostatic conditions, and careful clinical phenotyping. In most healthcare systems, this level of evaluation is not available through standard pathways. Patients receive a POTS diagnosis without subtyping — and treatment begins by trial and error rather than by pathophysiological reasoning.

The Body Under Siege

What Dysautonomia Does to a Human Life

The symptom spectrum of dysautonomia is one of the reasons it is so reliably missed. Because the autonomic nervous system governs so many organ systems, its dysfunction produces complaints that span every medical specialty. To the clinician trained to think within specialty boundaries — and trained to be suspicious of patients who present with symptoms across many specialties — the multi-system picture of dysautonomia looks, very easily, like somatisation, anxiety, or hypochondria. This interpretation is not merely unhelpful. It is, for many patients, the beginning of a years-long detour through the wrong parts of the medical system.

The breadth of what dysautonomia produces

Cardiovascular Palpitations, tachycardia on standing, chest pain or pressure, pre-syncope (near-fainting), syncope (fainting), exercise intolerance, shortness of breath on minimal exertion, cold extremities, mottled or livedo skin on lower limbs in upright position
Neurological & Cognitive Brain fog (cognitive impairment that fluctuates with posture), headache — particularly occipital or pressure-type — dizziness, visual disturbances including tunnel vision and visual greyout, tremor, numbness and tingling, migraine, difficulty with word retrieval and concentration
Gastrointestinal Nausea (frequently worse on standing), vomiting, bloating, abdominal pain, early satiety, gastroparesis (delayed gastric emptying), constipation and/or diarrhoea — reflecting autonomic control of gastrointestinal motility and secretion
Thermoregulatory Inability to tolerate heat (heat frequently exacerbates all symptoms), abnormal sweating (either excessive or absent in affected areas), cold intolerance, temperature dysregulation that does not correlate with ambient environment, flushing
Genitourinary Bladder urgency and frequency, incomplete bladder emptying, urinary retention in severe cases, sexual dysfunction — reflecting autonomic innervation of the bladder and pelvic floor
Fatigue and Sleep Profound fatigue that is disproportionate to activity level, post-exertional malaise (symptom worsening following physical or cognitive effort), non-restorative sleep, sleep-disordered breathing — frequently misread as depression, deconditioning, or chronic fatigue syndrome without autonomic investigation

The cardinal feature that cuts across all of these symptoms — and that is the most powerful diagnostic signal for clinicians willing to attend to it — is orthostatic dependence: the pattern of symptoms being reliably and substantially worse in the upright position and improved, often dramatically, when supine or when the legs are elevated. This positional relationship is not a subtle observation. In POTS, the improvement on lying down can be so rapid and so complete that a patient who seemed incapacitated can, within minutes of lying flat, appear and feel nearly well. This dramatic variability, rather than being interpreted as the physiological signature it is, is frequently used as evidence that the symptoms are not organic — that they are, in the language still used in too many clinics, functional, variable, or psychogenic.

A condition that resolves almost entirely when a person lies down and returns the moment they stand up is not psychosomatic. It is gravitational. The clue is in the physics.

The cognitive symptom — brain fog — deserves particular attention, because it is one of the most disabling aspects of dysautonomia and one of the least understood by clinicians who have not encountered it directly. Brain fog in POTS is not vagueness or mild distractibility. It is a concrete impairment in processing speed, word retrieval, working memory, and executive function that fluctuates with autonomic state. When standing reduces cerebral perfusion — which it does, measurably, in POTS, with reductions in cerebral blood flow velocity documented on transcranial Doppler — the brain begins to operate under conditions analogous to mild hypoxia. Patients who were previously high-functioning academically or professionally describe being unable to finish sentences, to remember words they have used a thousand times, to perform arithmetic they could once do in their sleep. This is not depression. It is cerebral hypoperfusion. And it improves when they lie down.

The Numbers

The Scale of What Is Being Missed

1–3M
Estimated POTS patients in the US alone; global figures are substantially higher and largely uncounted
4–6 yr
Average diagnostic delay from symptom onset to POTS diagnosis in multiple patient surveys conducted pre-2020
~75%
Proportion of POTS patients who are female; onset peaks in adolescence and young adulthood — the demographic medicine has most systematically dismissed

The demographic concentration of POTS in young women is not incidental to its diagnostic history. It is central to it. The condition's prevalence in a population that medicine has, across centuries and specialties, been most prone to pathologise as emotionally driven rather than organically ill has directly shaped how POTS has been received, investigated, and treated. The symptom that looks most like anxiety — racing heart, shortness of breath, dizziness, fatigue — is the symptom of POTS. The population most likely to be told their physical symptoms are psychological is young women. These two facts collide in every room where an undiagnosed POTS patient presents to a clinician who has not been trained to measure orthostatic heart rate.

The COVID-19 pandemic introduced a new and large cohort of post-infectious POTS patients — predominantly previously healthy adults who developed autonomic symptoms following acute COVID-19 infection. Long COVID-associated dysautonomia is now one of the most studied post-infectious autonomic syndromes in medical literature, having generated more research funding and clinical attention in four years than POTS received in the preceding two decades. This attention has been broadly beneficial: it has accelerated understanding of post-infectious mechanisms, generated new treatment evidence, and — perhaps most importantly — given POTS a degree of mainstream medical legitimacy it had previously struggled to achieve. The irony, noted bitterly by patients who spent years being dismissed before 2020, is that it took a pandemic affecting millions of people across all demographics to make autonomic dysfunction seem real to the medical establishment.

The Test That Changes Everything

Why POTS Is Not Diagnosed — and How It Should Be

The diagnostic test required to identify POTS is one of the simplest in medicine. In its most basic form, it requires a patient, a blood pressure cuff, a pulse oximeter or heart rate monitor, and the ability to measure heart rate in two positions: lying down for five to ten minutes, then standing. A rise of 30 or more beats per minute (or 40 or more in adolescents) sustained over the ten-minute standing period, in the presence of orthostatic symptoms, meets the diagnostic threshold. This test requires no expensive equipment, no specialist facility, and approximately fifteen minutes. It is not routinely performed in primary care. It is not routinely performed in emergency departments, where POTS patients frequently present. In many countries, it is not taught in standard medical curricula.

The more formal version — the tilt table test (TTT) — involves strapping a patient to a motorised table, moving them from horizontal to approximately 70 degrees upright, and monitoring heart rate, blood pressure, and symptoms over up to 45 minutes, with pharmacological provocation if the passive phase is non-diagnostic. The tilt table test can identify POTS, distinguish it from other forms of orthostatic intolerance including vasovagal syncope and orthostatic hypotension, and — with appropriate catecholamine measurement at each position — help with subtyping. Access to tilt table testing varies dramatically by geography, health system, and economic resources. In many public healthcare systems, waiting times for tilt table testing run to many months. In many low- and middle-income countries, the test is simply not available.

The Nasa Lean Test — practical active standing protocol

For patients and clinicians without access to tilt table testing, the NASA Lean Test is the most validated at-home/clinic alternative. The patient lies flat for ten minutes. Heart rate and blood pressure are recorded. The patient then stands and leans against a wall with feet 15cm from the wall (to reduce leg muscle pumping and better replicate passive orthostatic stress). Heart rate and blood pressure are recorded every two minutes for ten minutes, with symptoms documented throughout. A rise of ≥30 bpm (≥40 bpm in those under 19) is consistent with POTS. This protocol has been validated against tilt table testing and is recommended by multiple dysautonomia specialist organisations. It can be performed in any clinic room. It is still not routinely performed in most primary care settings.

Additional testing that characterises the condition beyond the core diagnosis includes autonomic reflex screening (assessing sudomotor, cardiovagal, and adrenergic function), quantitative sudomotor axon reflex testing (QSART) to assess small-fibre sudomotor nerve function, skin punch biopsy for intraepidermal nerve fibre density, plasma catecholamine levels in supine and standing positions, blood volume measurement (useful for hypovolemic subtype identification), and cardiac assessment including echocardiography to exclude structural cardiac causes of tachycardia. Many patients with POTS will never receive this full panel — either because their healthcare system does not offer it, or because they have not been referred to a specialist with the expertise to order and interpret it.

The Treatment Landscape

Managing Dysautonomia — What Works, What Doesn't, and Why the Answer Varies

There is no cure for most forms of dysautonomia. The treatment of POTS is symptomatic and management-focused — aimed at reducing the haemodynamic impact of orthostatic stress, improving quality of life, and enabling function. The evidence base for specific interventions is, relative to the scale of the problem, thin — a consequence of decades of under-funding and under-research — but it is growing, particularly in the wake of Long COVID. What follows is a medically grounded summary of the current treatment landscape, beginning with non-pharmacological approaches and moving through pharmacological options. The critical caveat — and it cannot be stated forcefully enough — is that treatment should be guided by subtype. Not all of the following is appropriate for all POTS patients.

Non-pharmacological foundations — these come first

In milder POTS presentations and as the foundation of management in all presentations, lifestyle and physical countermeasures are the most evidence-supported interventions available.

Volume expansion through fluid and sodium intake is the first-line non-pharmacological intervention for most POTS subtypes (with the significant exception of hyperadrenergic POTS). Guidelines from specialist centres typically recommend a fluid intake of two to three litres of water per day and a sodium intake of three to five grams daily (from food and supplementation), significantly above standard dietary recommendations. This approach reduces plasma volume deficit and attenuates the haemodynamic response to standing. The evidence base is consistent; the main barrier is adherence and the misunderstanding by non-specialist clinicians that high salt intake is universally inadvisable.

Physical countermanoeuvres — muscle tensing, leg crossing, squatting, physical compression of the abdomen or lower limbs — reduce venous pooling acutely during prolonged standing and can abort or delay orthostatic symptoms. Compression garments (waist-high, ideally with abdominal compression in addition to lower limb compression) are widely recommended and modestly evidence-supported. Elevating the head of the bed by 10–20 degrees during sleep reduces overnight diuresis and helps maintain plasma volume.

Exercise rehabilitation is one of the most robustly evidence-supported long-term interventions in POTS, and also one of the most frequently misapplied. The landmark work from the Baker Heart Research Institute and the University of Texas Southwestern has demonstrated that a structured, graduated exercise programme — beginning with recumbent and semi-recumbent exercise (rowing, swimming, recumbent cycling) that avoids the orthostatic challenge of upright activity, and progressively introducing upright exercise over months — produces meaningful and sustained improvement in POTS symptoms in a substantial proportion of patients. The critical nuance: this evidence applies to a carefully structured, medically supervised protocol, not to generic advice to "exercise more." Telling a patient with POTS to simply exercise more without structure, without appropriate recumbent initiation, and without pacing guidance can trigger post-exertional malaise and worsen the condition. This is a distinction that most non-specialist clinicians and many physiotherapists do not make.

Pharmacological options — by evidence and indication

Medication Mechanism Evidence & Notes Caveat
Fludrocortisone First-line Synthetic mineralocorticoid; promotes renal sodium and water retention, expanding plasma volume Long-standing use in dysautonomia; modestly evidence-supported for symptomatic improvement in hypovolemic/neuropathic subtypes. Oral, once daily. Can worsen hypertension; not appropriate for hyperadrenergic POTS. Monitor electrolytes — hypokalaemia is a risk. Not recommended in pregnancy without specialist oversight.
Midodrine First-line Alpha-1 adrenergic agonist; causes peripheral vasoconstriction, reducing venous pooling on standing One of the best-evidenced pharmacological options; multiple randomised controlled trials support improvement in orthostatic symptoms. Short duration of action — typically dosed 3x daily, not within 4 hours of lying down. Supine hypertension is a significant risk — patients must not lie flat within hours of dosing. Causes pilomotor erection and scalp paraesthesia (common, generally benign). Avoid in hyperadrenergic subtype.
Ivabradine First-line (rate) Selective If channel blocker; reduces heart rate by inhibiting the sinus node without affecting blood pressure or contractility Multiple randomised trials and large case series support its use for heart rate reduction in POTS. Unlike beta-blockers, does not reduce blood pressure — an advantage in normotensive patients. Now first-line at many specialist centres. Not appropriate in bradycardia, significant SA node dysfunction, or pregnancy. Does not address the underlying haemodynamic problem — only the tachycardia symptom. Long-term evidence still accumulating.
Beta-blockers (low-dose propranolol) Second-line Non-selective beta-blockade reduces heart rate response to standing Low-dose propranolol (10–20mg) has evidence for symptom reduction in POTS. Higher doses frequently not tolerated due to fatigue and hypotension. Preferred over higher doses in most specialist guidance. Can worsen fatigue and exercise intolerance — both already significant symptoms in POTS. May cause hypotension. Not first-choice in hyperadrenergic POTS where response can be paradoxical.
Pyridostigmine Second-line Acetylcholinesterase inhibitor; enhances ganglionic neurotransmission, improving peripheral vasoconstriction without significantly increasing supine blood pressure Particularly useful in neuropathic POTS; shown to improve orthostatic tolerance with a favourable supine blood pressure profile. May be especially appropriate in patients where midodrine causes unacceptable supine hypertension. Gastrointestinal side effects (nausea, cramping, diarrhoea) are common and dose-limiting. Less evidence than midodrine or ivabradine overall.
Clonidine Hyperadrenergic Central alpha-2 agonist; reduces sympathetic outflow, lowering norepinephrine levels Specifically useful in hyperadrenergic POTS where norepinephrine-mediated tachycardia and hypertension dominate the picture. Evidence base is largely observational. Causes significant sedation and dry mouth; rebound hypertension on abrupt withdrawal. Only appropriate in confirmed or strongly suspected hyperadrenergic subtype.
IV Saline infusion Acute / rescue Direct plasma volume expansion; acutely improves haemodynamic stability Consistently reported by patients as one of the most rapidly effective interventions for severe exacerbations. Used as rescue therapy in acute decompensation. Regular infusions used in refractory cases at some specialist centres. Not a sustainable long-term strategy; IV access risks and infusion reactions with repeated use. Access varies widely by health system — many patients cannot access this even when clinically indicated.

Several emerging therapeutic targets deserve mention, though they remain investigational or used off-label in most settings. Low-dose naltrexone has been reported anecdotally and in small series to improve fatigue and brain fog in POTS, possibly via immunomodulatory and mast-cell-stabilising mechanisms. Intravenous immunoglobulin (IVIG) has shown promise in autoimmune-mediated dysautonomia, particularly post-infectious POTS with documented autoantibody involvement. Antihistamines and mast cell stabilisers (such as cromolyn sodium, ketotifen, and cetirizine) are widely used in patients where POTS co-occurs with mast cell activation syndrome, with reports of meaningful symptom improvement in that specific population. None of these has the randomised controlled trial evidence base required for guideline inclusion, but they are increasingly used and studied at specialist centres.

The Comorbidities

POTS Does Not Travel Alone

Like CCI, POTS exists within a cluster of related, frequently co-occurring conditions. Understanding this cluster is essential, both for diagnosis and for treatment — because treating POTS in isolation, without addressing its companions, produces incomplete and often frustrating results.

The recognition of this cluster has been one of the most important developments in the field over the past decade. It means that a patient presenting to a dysautonomia specialist is frequently presenting with not one condition but three, four, or five — each interacting with and amplifying the others, and each requiring its own strand of investigation and management. The cardiologist sees the POTS. The rheumatologist sees the hypermobility. The allergist sees the mast cell activation. Nobody, in the standard referral pathway, sees the person as a whole. The patient — who has often spent years reading, connecting, and building a map of their own pathophysiology — frequently knows more about the landscape of their conditions than any individual specialist they encounter. This should embarrass the system. It mostly doesn't.

Long COVID

The Pandemic That Made Dysautonomia Visible

The COVID-19 pandemic created, in a very short time, a large and demographically diverse population of people with new-onset autonomic dysfunction. Post-acute sequelae of SARS-CoV-2 infection (PASC) — Long COVID — includes POTS and other forms of dysautonomia as among its most common and most debilitating manifestations. Estimates from Long COVID cohort studies suggest that autonomic symptoms are present in 30–60% of patients with persistent post-acute symptoms, and that POTS or POTS-like physiology accounts for a significant proportion of the exercise intolerance, brain fog, fatigue, and palpitations that define the syndrome.

The Long COVID dysautonomia population has illuminated several important things. First, that POTS can develop acutely in previously healthy individuals following a viral trigger, confirming post-infectious mechanisms that POTS patient communities had been describing for decades — and being dismissed for. Second, that autoimmune mechanisms are likely involved in a subset of cases, with studies documenting autoantibodies against autonomic receptors in Long COVID cohorts. Third — and most painfully for the pre-pandemic POTS community — that when the same condition affects a larger, more demographically representative, and media-visible population, it becomes real in a way it apparently was not before.

POTS was not taken seriously until it happened to enough people that ignoring it became politically untenable. The patients who had it before the pandemic already knew that. They had known it for years. They had been told they were anxious.

The research acceleration generated by Long COVID has produced several important therapeutic insights — particularly around immunotherapy in autoimmune-mediated dysautonomia, around the role of mast cell activation in post-infectious autonomic dysfunction, and around the mechanisms of cerebral hypoperfusion in POTS. Whether the research funding generated by Long COVID will translate into sustained, long-term investment in autonomic disorders more broadly — including in the pre-COVID POTS population — remains to be seen. The patient community is watching with cautious and well-earned scepticism.

What Needs to Change

What Medicine Owes These Patients

The story of dysautonomia in modern medicine follows the same arc as the story of CCI, and the same arc as the story of every condition in this series. A condition that is structurally complex, multi-systemic, diagnostically invisible to standard-of-care approaches, and concentrated in a patient population medicine has consistently undertreated has been allowed to exist in a space of near-institutional invisibility for decades. The patients who have it have been told, with numbing and consistent regularity, that what is happening to them is not happening — or is happening, but only because of how they think and feel rather than because of physiology that can be measured and explained.

What needs to change is not mysterious and is not expensive to begin. Medical students and junior doctors need to be taught what the autonomic nervous system is, what POTS is, and how to perform an active standing test. This is a twenty-minute addition to medical education that would, across a career, change thousands of diagnostic trajectories. Emergency medicine physicians need a protocol for assessing orthostatic heart rate in patients presenting with syncope, palpitations, and unexplained fatigue. Neurologists, cardiologists, rheumatologists, and gynaecologists — the specialties most likely to see POTS patients first — need shared care pathways that funnel appropriate patients toward autonomic evaluation rather than psychiatric referral. Physiotherapists prescribing exercise to chronically fatigued patients need to know that generic aerobic exercise advice can worsen POTS, and what a recumbent-first protocol actually looks like.

What patients consistently report they need

Based on dysautonomia patient surveys and advocacy submissions: a clinician who performs and interprets an orthostatic heart rate measurement before dismissing their symptoms; access to tilt table testing within a reasonable timeframe; POTS subtyping to guide treatment selection; physiotherapy from practitioners trained in dysautonomia-appropriate exercise protocols; recognition that brain fog is a physiological symptom of cerebral hypoperfusion, not a psychological one; access to IV saline infusion when oral fluid loading is insufficient; integration of care between specialties rather than sequential, disconnected specialist consultations; and an end to psychiatric re-labelling of orthostatic symptoms in young women.

Research investment is the longer structural need. The treatment evidence base for POTS is improving but remains thin relative to the scale of the condition. There are no approved pharmacological treatments for POTS in the United States, United Kingdom, or the European Union — every medication used is either off-label or used for associated conditions. This is not because POTS is too rare to warrant investigation. It is because investment did not follow the condition until Long COVID forced it. Regulatory pathways for autonomic conditions need development. Biomarker research — identifying the immunological, neuropathological, and haemodynamic signatures that will allow reliable subtyping and treatment matching — needs sustained funding beyond the current pandemic-focused horizon.

The Call

If You Recognise Yourself in This

If you are reading this and recognising your own life in it — the racing heart every time you stand, the fog that descends when you are upright, the years of being told you are anxious, the exhaustion of having to prove that something is wrong — then this section is for you.

Your symptoms have a physiological explanation. The heart rate you feel is real and measurable. The cognitive changes when you stand are a consequence of reduced cerebral perfusion, not psychological fragility. The fact that lying down makes you better is not evidence that nothing is wrong. It is the most important diagnostic clue that something is specifically, mechanically, measurably wrong — and that what is wrong is in your autonomic nervous system.

The path to diagnosis may require you to advocate for yourself in ways that feel unjust. It is unjust. You may need to ask — to insist — that a clinician measures your heart rate lying down and standing up. You may need to document this yourself at home using the NASA Lean Test protocol. You may need to bring the documentation to an appointment. You may need to ask for a referral to a cardiologist or neurologist with an interest in autonomic disorders. You may need to ask for that referral more than once.


Dysautonomia is not a condition that politely confines itself. It reaches into every corner of a life — the inability to cook a meal standing up, to sit through a meeting, to attend school or university, to maintain a career. It reorders priorities in ways that people who have not experienced it find difficult to understand and easy to dismiss. The people who have it did not choose a condition that is invisible on standard investigations, dismissed by standard clinicians, and concentrated in a demographic that medicine has historically pathologised. They found themselves there. And the healthcare system's task — the task it has not yet adequately performed — is to meet them there, with knowledge and with measurement, before another decade passes.

The test takes fifteen minutes. The measuring tape costs nothing. What it would take to find POTS in the people who have been living with it undiagnosed is not resources. It is the decision to look.

This is the second in a series of articles on the conditions that fall through the widest cracks in modern medicine. Next: Tethered Cord Syndrome — the tension at the base of the spine that pulls on the nervous system from below, and the patients who spent years being told the feeling of being trapped inside their own body was psychological.